Click Therapeutics

Company profile

About Click Therapeutics

Click Therapeutics is redefining modern medicine by developing, validating, and commercializing software as prescription medical treatments for people with unmet medical needs. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software to create a new way to treat disease. The company's platform-based approach targets diseases from multiple angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions. Click develops two types of solutions: Prescription Digital Therapeutics (PDTs) that function as standalone software treatments, and Software-Enhanced Drugs (SE Drugs) that combine software with pharmacotherapy to deliver added clinical benefit compared to drug alone. Their platform can target any disease, symptom, or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. The company's products are regulated by the FDA as medical devices, with evidence-based treatment claims validated through rigorous randomized clinical trials. Their launched and FDA-authorized products include CT-152 (Rejoyn) for major depressive disorder, AspyreRx for type 2 diabetes, and CT-132 for episodic migraine. Click maintains ISO 13485:2016 certification for medical device quality management and ISO/IEC 27001:2022 certification for information security, demonstrating their commitment to delivering safe and effective digital treatments through a platform backed by over a decade of development.

Company description · Click Therapeutics official website